August 16, 2010 — The first commercial use for a prostate-rectum separation system in prostate cancer patients undergoing radiation therapy has taken place. Professor Michael Eble and Dr. Michael Pinkawa of the Aachen University Hospital, Aachen, Germany, performed an implantation of SpaceOAR system. The SpaceOAR hydrogel (from spacing Organs At Risk) is a CE mark-approved system from Augmenix Inc., designed to be a tissue compatible, absorbable spacer to reduce radiation injury to healthy tissues. "The potential for radiation injury to nearby healthy tissues is always a concern for radiation oncologists, and the SpaceOAR hydrogel is a simple, easy-to-use tool that should reduce undesirable rectal radiation in prostate cancer patients. I look forward to using SpaceOAR hydrogel in my prostate cancer population and in other pelvic tumors such as vaginal, cervical and endometrial cancers," said Pinkawa, radiation oncologist. Since the prostate lies directly over the rectum, prostate radiation treatment always results in some rectal radiation which can lead to pain, rectal bleeding, urgency and other serious complications. This injury potential forces a treatment compromise, between delivering enough radiation to kill the cancer and having acceptable complication rates. The Augmenix technology can alter that compromise by moving the organs at risk away from the high intensity radiation zone. SpaceOAR System is a synthetic hydrogel composed of approximately 90 percent water, with the remaining solids being cross-linked polyethylene glycol (PEG). Injected as a liquid, the material solidifies in the body to form an absorbable hydrogel that maintains space between the prostate and rectum during radiation therapy, and then gradually liquefies and is absorbed. In a procedure lasting minutes, Pinkawa used transrectal ultrasound guidance to inject the hydrogel through an 18-gauge needle using only a local perineal block. "I am extremely enthusiastic about this technology and truly believe it will offer a new level of hope to men facing treatment for prostate cancer and potentially other malignancies," said Jeff Michalski, M.D., vice chairman and professor, Washington University, St. Louis, Mo. Augmenix is a privately held company based in Waltham, Mass., focused on the development and commercialization of radiation oncology products using its proprietary hydrogel technology.
News | August 16, 2010
First Use of System for Prostate-Rectum Separation in Radiation Therapy
Technology | Radiation Therapy | December 10, 2018
RaySearch has decided to develop a treatment control system, RayCommand, to act as a link between its RayStation...
Videos | Radiation Therapy | December 06, 2018
News | Artificial Intelligence | December 04, 2018
Mirada Medical, a leading global brand in medical imaging software, will form part of an artificial intelligence (AI)...
Sponsored Content | Videos | Radiation Oncology | November 30, 2018
Accuray's philosophy is to personalize treatments to exactly fit the patient.
Videos | Artificial Intelligence | November 28, 2018
This is an example of how artific...
News | Proton Therapy | November 21, 2018
The Ohio State University Wexner Medical Center and the Arthur G. James Cancer Hospital and Richard J. Solove Research...
News | Prostate Cancer | November 19, 2018
Higher Pretreatment Immune Inflammatory Levels Linked to Lower Disease-Free Survival in Prostate Cancer
Data from a validation study of a high-risk prostate cancer trial suggests that higher levels of pretreatment...
News | Women's Health | November 14, 2018
Disposable device manufacturer Merit Medical Systems Inc. announced the closing of a definitive merger agreement to...
Videos | ASTRO | November 08, 2018
ITN Editor Dave Fornell took a tour of some of the most innovative technologies on display on the expo floor at the
360 Photos | 360 View Photos | November 07, 2018
Fujifilm's first FDA-cleared compu...